Cargando…

Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-Cell lymphoma

Detalles Bibliográficos
Autores principales:	Asokan, Ishan, Singh, Sanminder, Moesch, John, Ho, Jonhan, Akilov, Oleg E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753052/ https://www.ncbi.nlm.nih.gov/pubmed/35036504 http://dx.doi.org/10.1016/j.jdcr.2021.11.022

Ejemplares similares

CD56(−) extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white man
por: Vainder, Charles, et al.
Publicado: (2016)

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019)

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Mogamulizumab Treatment in a Hemodialysis Patient with Adult T-Cell Leukemia/Lymphoma
por: Yoshihara, Mari, et al.
Publicado: (2014)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
por: Caruso, Laura, et al.
Publicado: (2022)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

Alopecia areata after mogamulizumab treatment
por: Raval, Neel S., et al.
Publicado: (2021)

Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome
por: Breen, Ilana D., et al.
Publicado: (2021)

The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab
por: Wang, Lan, et al.
Publicado: (2020)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
por: Hirosawa, Makoto, et al.
Publicado: (2022)

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
por: Phillips, Adrienne A., et al.
Publicado: (2019)

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023)

Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab
por: Nosaka, Kisato, et al.
Publicado: (2021)

Alopecia areata-like presentations with mogamulizumab therapy
por: Kincaid, Colin M., et al.
Publicado: (2023)

Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
por: Jouandet, Marie, et al.
Publicado: (2022)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
por: Xiao, Amy, et al.
Publicado: (2022)

Comparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis
por: Alizadeh, Narges, et al.
Publicado: (2014)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
por: Ishida, Takashi, et al.
Publicado: (2017)

Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
por: Tanaka, Hiroaki, et al.
Publicado: (2017)

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
por: Horwitz, Steven, et al.
Publicado: (2021)

A novel mouse model of cutaneous T‐cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy
por: Nakahashi, Keiko, et al.
Publicado: (2022)

Fluconazole/tioconazole: Allergic contact dermatitis following cross reactivity: case report
Publicado: (2021)

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review
por: TRAGER, Megan H., et al.
Publicado: (2020)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
por: Trum, Nicholas A., et al.
Publicado: (2021)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
por: Lama, Carine M., et al.
Publicado: (2023)

Cutaneous adverse reactions and anti-tumor effects of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma
por: Yonekura, Kentro, et al.
Publicado: (2015)

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas
por: Kitadate, Akihiro, et al.
Publicado: (2018)

Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab
por: Westergaard, Sarah A., et al.
Publicado: (2020)

Successful treatment strategy in corporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report
por: Nakata, Keiichi, et al.
Publicado: (2020)

Head and Neck Lymphoma in an Iranian Population
por: Shamloo, Nafiseh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_npbbd099tk3uec91555abqb85t